Convelo Therapeutics
Dr. Stubblefield’s background is in drug discovery and development for retinal, neurological, and inflammatory disorders. Most recently, Dr. Stubblefield worked at Harrington Discovery Institute helping to guide academic drug discovery programs through the development pathway. She also served as a senior scientist at Athersys focused on development of new clinical indications for MultiStem and development of mechanism of action and potency assays. Dr. Stubblefield received her B.S. in Biology from the University of Akron and her PhD in Molecular Biology from Case Western Reserve University.
Convelo Therapeutics
Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimer’s. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families.